NHS England plans £105m ferric carboxymaltose injection framework
NHS England is inviting suppliers to engage ahead of a planned national framework for ferric carboxymaltose injection, an iron replacement therapy.
Written with data automation, every figure verified against the official notice · · 1 min read
NHS England has published a planned procurement notice for a national framework for ferric carboxymaltose injection, valued at £105m. The notice invites suppliers planning to introduce the molecule to contact the MPSC New Market Developments Team before a formal tender process begins.
Key facts
buyer
NHS England
value
£105m (estimated)
supplier
Planned procurement; not yet awarded
published
14 July 2026
procedure or type
Planned procurement notice for a national framework
NHS England is consulting the market on a planned framework for ferric carboxymaltose injection, a treatment used to address iron deficiency. The estimated value is £105m across a single lot.
This is a planned procurement notice, which means no formal tender has opened yet. It is an early market engagement tool: NHS England is signalling intent and inviting suppliers with plans to enter or expand in this space to make contact and shape the upcoming process.
Suppliers interested in introducing ferric carboxymaltose injection, or with questions about the procurement, should email the MPSC New Market Developments Team. The contact points are Barbara Sly, Marie Graney and Katie Noonan at NHS England. Queries should be directed to barbara.sly@nhs.net, marie.graney1@nhs.net, and katie.noonan1@nhs.net.